Archive for the ‘Affymax’ Category

Affymax spikes after expert panel backs new anemia drug rival to Amgen

Shares of Affymax spiked more than 25% this morning as investors got a chance to show their enthusiasm for the big support FDA experts provided Wednesday afternoon for the biotech’s experimental anemia drug peginesatide. The panelists voted 15 to …

Affymax investors bullish on FDA review of Amgen anemia drug rival

Facing an expert panel review for peginesatide on Wednesday, FDA staffers gave Affymax ($AFFY) a solid boost in confidence this morning with an agency review that backed the once-monthly anemia treatment as equivalent to Amgen’s ($AMGN) blockbuster tre…

Potential rival to Amgen’s anemia drug faces big day with FDA advisers

Affymax ($AFFY) has been part of a “David and Goliath” story for years, with the small biotech developing an anemia drug called peginesatide for kidney dialysis patients that could rival Epogen, from industry giant Amgen ($AMGN), if approved….